Dosing factor VIIa (recombinant) in nonhemophiliac patients with bleeding after cardiac surgery

American Journal of Health-System Pharmacy

Volumn 64, Issue 17, 2007, Pages 1808-1812

  Johnson, Sarah J ^a,b   Ross, Mary B ^c,d   Moores, Kevin G ^b,e  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UIHC   (United States)

^d UICP ^*

^e UICP   (United States)

Author keywords

Dosage; Factor VIIa; Hemorrhage; Hemostatics; Surgery; Toxicity

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A; RECOMBINANT PROTEIN;

ARTERY THROMBOSIS; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BRAIN HEMORRHAGE; BRAIN INFARCTION; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HEART SURGERY; HEMOPHILIA A; HEMOPHILIA B; HUMAN; LUNG EMBOLISM; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; TREATMENT RESPONSE; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; HEMOSTASIS; METHODOLOGY; THORAX SURGERY;

CLINICAL TRIALS; FACTOR VIIA; HEMOPHILIA A; HEMOSTASIS, SURGICAL; HUMANS; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS; THORACIC SURGERY; THROMBOEMBOLISM;

EID: 34848901435     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060398     Document Type: Review

References (29)

1. Moulton MJ, Creswell LL, Mackey ME et al. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg. 1996; 111:1037-46.
2. Despotis GJ, Avidan MS, Hogue CW. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg. 2001; 72:S1821-31.
3. Lam MS, Sims-McCallum RP. Recombinant factor VIIa in the treatment of non-hemophiliac bleeding. Ann Pharmacother. 2005; 39:885-91.
4. Martinowitz U, Kenet G, Segal E et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma. 2001; 51:431-8.
5. Mayer SA, Brun NC, Begtrup K et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005; 352:777-85.
6. Diprose P, Herbertson MJ, O'Shaughnessy D et al. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth. 2005; 95:596-602.
7. NovoSeven (coagulation factor VIIa [recombinant]) package insert. Princeton, NJ: NovoNordisk; 2005 Oct.
8. Fleming T. Red book 2007: pharmacy's fundamental reference. Montvale, NJ: Thomson PDR; 2007.
9. Lusher JM, Roberts HR, Davignon G et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia. 1998; 4:790-8.
10. Vanek T, Straka Z, Hrabak J et al. Use of recombinant activated factor VII in cardiac surgery for an effective treatment of severe intractable bleeding. Jpn Heart J. 2004; 45:855-60.
11. Aldouri M. The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophiliac patients. Pathophysiol Haemost Thromb. 2002; 32(suppl 1):41-6.
12. Flynn JD, Pajoumand M, Camp PC Jr et al. Recombinant factor VIIa for refractory bleeding following orthotopic heart transplantation. Ann Pharmacother. 2004; 38:1639-42.
13. Dementieva I, Trekova N, Sandrikov V. Use of NovoSeven in cases with massive bleeding following surgery with extracorporeal circulation. Crit Care. 2004; 8:P137. Abstract.
14. Diprose P, Gill R, O'Shaughnessy D et al. Factor VIIa for severe cardiac surgical bleeding. Anesth Analg. 2003; 96:SCA1-141. Abstract.
15. Hyllner M, Houltz E, Jeppsson A. Recombinant activated factor VII in the management of life-threatening bleeding in cardiac surgery. Eur J Cardiothorac Surg. 2005; 28:254-8.
16. Aggarwal A, Malkovska V, Catlett JP et al. Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage. Thromb J. 2004; 2:9.
17. Stratmann G, Russell IA, Merrick SH. Use of recombinant factor VIIa as a rescue treatment for intractable bleeding following repeat aortic arch repair. Ann Thorac Surg. 2003; 76:2094-7.
18. Raivio P, Suojaranta-Ylinen R, Kuitunen AH. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann Thorac Surg. 2005; 80:66-71.
19. Halkos ME, Levy JH, Chen E et al. Early experience with activated recombinant factor VII for intractable hemorrhage after cardiovascular surgery. Ann Thorac Surg. 2005; 79:1303-6.
20. Egan JR, Lammi A, Schell DN et al. Recombinant activated factor VII in paediatric cardiac surgery. Intensive Care Med. 2004; 30:682-5.
21. Leibovitch L, Kenet G, Mazor K et al. Recombinant activated factor VII for life-threatening pulmonary hemorrhage after pediatric cardiac surgery. Pediatr Crit Care Med. 2003; 4:444-6.
22. Naik VN, Mazer CD, Latter DA et al. Successful treatment using recombinant factor VIIa for severe bleeding post cardiopulmonary bypass. Can J Anaesth. 2003; 50:599-602.
23. Bishop CV, Renwick WE, Hogan C et al. Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery. Ann Thorac Surg. 2006; 81:875-9.
24. Von Heymann C, Kastrup M, Redlich U et al. Experiences with recombinant activated factor VII for refractory bleeding after cardiac surgery: a retrospective analysis. Anesthesiology. 2003; 99:A442. Abstract.
25. Karkouti K, Beattie WS, Wijeysundera DN et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion. 2005; 45:26-34.
26. Von Heymann C, Redlich U, Jain U et al. Recombinant activated factor VII for refractory bleeding after cardiac surgery: a retrospective analysis of safety and efficacy. Crit Care Med. 2005; 33:2241-6.
27. Romagnoli S, Bevilacqua S, Gelsomino S et al. Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery. Anesth Analg. 2006; 102:1320-6.
28. Meng ZH, Wolberg AS, Monroe DM et al. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma. 2003; 55:886-91.
29. O'Connell KA, Wood JJ, Wise RP et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006; 295:293-8.